Goodwin Procter attorneys advised client Foundation Medicine on all aspects of its strategic transaction with Roche, including a tender offer component, a primary investment, and R&D and commercial collaboration agreements. The transaction will advance Foundation Medicine’s market-leading position in molecular information and genomic analysis and provide Roche an opportunity to optimize the identification and development of treatment options for cancer patients. More >>

David R. Sullivan is joining Murtha Cullina’s Business and Finance Department. With more than thirty years of experience, his practice includes all corporate, limited liability company and federal and state taxation matters, including advising clients with respect to business formation, business purchase and sale transactions, financings, tax credits and exit strategies. He represents private companies, banks, tax exempt entities and public agencies. More >>

Ropes & Gray is advising Dunkin’ Brands Group, Inc. on the planned refinancing of its senior secured credit facility with a new $2.4 billion securitized financing facility. The new facility is expected to be comprised of $2.3 billion of senior fixed-rate term notes and $100 million of variable funding notes. Dunkin’ Brands is the parent company of Dunkin’ Donuts and Baskin-Robbins. The offering was announced Jan. 6 and is expected to close in the first quarter of 2015. More >>

Goodwin Procter attorneys recently advised TA Associates, its portfolio company Fotolia and Fotolia’s CEO and Co-Founder Oleg Tscheltzoff on the announced sale of Fotolia to Adobe for an enterprise value of $800 million. The transaction is expected to close in the first quarter of 2015. TA and Tscheltzoff own Fotolia together with the Company’s largest shareholder, KKR. Financial terms of the transaction were not disclosed. More >>

Ropes & Gray advised Cubist Pharmaceuticals, Inc. in its acquisition by Merck, which agreed to acquire Cubist for $102 per share in cash. The total transaction value, including debt, is approximately $9.5 billion. Cubist, a leading global biopharmaceutical company based in Lexington, Mass., focuses on the research, development and supply of antibiotics to treat infections caused by a broad range of drug-resistant bacteria. The deal was announced Dec. 8. More >>

Ropes & Gray advised Chicago- and Nashville-based Cressey & Company, a leading health care-focused private investment firm, in the formation of Cressey & Company Fund V, LP. Fund V, which closed with a combined $615 million in limited partner and general partner capital commitments, will focus on investing in premier platform businesses and accelerating growth organically and through acquisitions. The fund launched in July 2014; its closing was announced Dec. 8. More >>